Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Energy-efficient digital outdoor billboards for sustainable advertising (DynamicColor)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Israel
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2019)
Start date: 2019-04-01
End date: 2019-07-31
Duration (months): 4.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Digital billboards are between 6 to 10 times more profitable than traditional printed billboards. The higher profitability is attributed to a higher turnover rate of displayed ads – thus, higher income – and to the reduced costs associated with changing the ads. Whereas traditional billboards require large format printers, a special high-altitude team, a 4x4 truck with crane and produce waste every time the ad is changed, digital billboard ads are changed remotely and can quickly publish new campaigns. State-of-the-art digital billboards are made of light emitting diodes – LEDs – that are lit 24h a day, every day. A 60 m^2 LED billboard uses up to 300 MWh/year depending on the display resolution, which is around €30,000/year – the equivalent to 17 average EU households. We have developed and energy efficient digital billboard that has low OPEX and reduces environmental impact of current outdoor billboard solutions – less than 5% of the energy consumption compared to state-of-the-art LED billboards and zero waste compared to printed billboards that have to be changed every 10 days. We target billboard owners and advertising agencies who which to increase revenues by adopting digital billboards but are discouraged by the underachieving performance of LED billboards and their high OPEX costs. The out of home advertising market was forecasted to grow at 4% CAGR to reach €28 bn by 2021. Billboards represent 44% of market share - €10.8 bn – of which 98% are still non-digital billboards, which presents a big market opportunity for a high-performance technology. We are aiming to start scale up of our technology by the end of 2019, targeting €33M in revenues by 2023 with 88+ FTEs. In this Phase 1 project we will investigate our target market segments & develop a go-to-market strategy.

Keywords: billboards,advertising,digital display
Novel Catheter for the Diagnosis of Cardiovascular Disease (Wirecath)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Sweden
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2019)
Start date: 2019-08-01
End date: 2020-01-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Cavis Technologies has an objective to clinically validate and commercialise Wirecath – its novel medical device for assessing severity of narrowings in the coronary arteries and myocardial disease. It has the potential to substantially reduce management costs in cardiovascular disease by improving its diagnosis, and thus, increasing opportunity for timely prevention of disease progression and its severe complications, such as angina, shortness of breath and heart attack. Wirecath has several premium features over competing solutions. These are an unique high accuracy, superior manoeuvrability and cost-effectiveness. Its simple and robust design bases on a unique position of pressure sensor and resistance to hydrostatic error, that standard pressure wires are liable to. Given that hydrostatic error often leads to misdiagnosis of the coronary artery disease severity, Wirecath optimises diagnostic accuracy and offers long-lasting benefits to patients, cardiologists and healthcare providers. The unique accuracy allow new methods to be developed, applicable to another large patient group that has non-obstructive CAD, with no good diagnosis tools available today. With this project, Cavis intends to support 2019’s commercial launch of Wirecath and plan further product development and large-scale clinical evaluation studies that will follow the first-in-man study planned for 2019. Cavis’ current research and development activities are supported by investment from shareholders and numerous innovation grants. Cavis plans to apply for SME Instrument Phase 2 funding to perform clinical studies that will build trust in its unique features and increase its commercial value. With 1.9 million deaths a year, cardiovascular diseases are the leading cause of death in the EU and place a considerable burden on healthcare systems and government budgets. Prevention and treatment of various cardiovascular diseases, is of a high strategic priority.

Keywords: coronary physiology,fractional flow reserve,coronary flow reserve
Automated LCD Recycling series 4000 (ALR4000)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Ireland
Call: SME instrument (H2020-SMEInst-2018-2020-2, 2019)
Start date: 2019-10-01
End date: 2023-03-31
Duration (months): 42.0
Total project cost (EUR): 2773599.0
EU funding (EUR): 1941519.0
Participants: 1
Project status: SIGNED

Votechnik is a high potential start up company developing a one of its kind fully automated LCD recycling technology for global markets. Approximately 250 million LCDs are sold globally per annum and all require recycling at their end of life. In Europe the WEEE directive stipulates that hazardous components must be removed from LCDs such as mercury containing CCFLs and liquid crystal containing sheets. While manual disassembly to remove these components is slow (5LCDs p/hr), costly and poses a health risk for the workers, there are limited solutions available on the market. Amoung these are specialised shredding technology for mercury wastes which requires high volume of mercury waste (including lamps and CCFL) to be economical (1t/hr) while the only alternative is semi-automated technologies that still require manual labour to separate the mercury tubes resulting in a slow process (12 LCDs p/hr). The Votechnik technology is a state of art robotics solution for high speed depollution of LCDs at 60 LCDs /hr, fully automated and safe capture of mercury. The ALR4000 project is focused on developing the TRL 8 verison of the technology and deploying it as 3 reference sites in key markets for North EU, South EU and USA. Votechnik intend on achieving a 10 sales of the technology from the demonstrations before the end of the project.

Keywords: recycling,lcds,automation,waste electronics,environment,critical raw materials,circular economy
Exponential Amplification and Rapid Detection of miRNAs using DNA-Quantum Dot Bioconjugates for Disease Diagnostics (AmpiDots)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Switzerland
Call: Marie Skłodowska-Curie Individual Fellowships (IF-EF) (H2020-MSCA-IF-2015, 2015)
Start date: 2017-01-01
End date: 2018-12-31
Duration (months): 24.0
Total project cost (EUR): 187419.6
EU funding (EUR): 187419.6
Participants: 1
Project status: CLOSED

Accurate and timely diagnosis is critical in the treatment of all diseases. Researchers are constantly discovering new links between specific biomolecules and diseases, often uncovering ‘panels’ of markers with high sensitivity and specificity for disease diagnostics. However, our current diagnostic tools are unable to take advantage of these panels as they lack sensitivity, or are too costly and slow for practical application. Accordingly, new technologies that can help transform these fundamental discoveries into revolutionary clinical tools are in high demand. These must be rapid, efficient, robust and cost-effective. To this end, I will develop a new rapid diagnostic assay that combines the unique functional properties of fluorescent nanomaterials and enzymes. The core technology is an advanced nanoparticle-biomolecule construct consisting of highly fluorescent ‘quantum dot’ inorganic nanoparticles coated with DNA. These nanobioconjugates (termed ‘AmpiDots’) act simultaneously as both templates for isothermal amplification of target miRNAs and as highly sensitive fluorescent sensors. The result will be a rapid, highly sensitive, versatile and efficient assay that can detect multiple targets simultaneously and give a robust signal for assay readout. A critical aspect of the work will be the use of advanced microfluidic-based analytical systems to optimise the assay and to study the unique phenomena that arise when enzymes interact with nanoparticles.

Keywords: nanoparticles,quantum dots,isothermal amplification,expar,enzymes
Real time analysis of tablet and capsule dosage during pharmaceutical manufacturing (ATRS Instrument)

Framework: Horizon 2020 — Industrial Leadership
Programme: Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology
Theme: Nanotechnologies
Action type: SME instrument
Countries involved: United Kingdom
Call: Accelerating the uptake of nanotechnologies, advanced materials or advanced manufacturing and processing technologies by SMEs (H2020-SMEINST-1-2014, 2014)
Start date: 2015-04-01
End date: 2015-09-30
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

The objective of the overall innovation project is to develop a novel instrument to measure and control pharmaceutical drug potency during manufacture at sub-second analysis speeds. This will significantly reduce the cost of quality testing, reduce the dosage variability that a patient receives, reduce production waste and solvent disposal and address challenging new regulatory testing guidelines. Pharmaceutical companies, in response to regulators (such as the US FDA) setting direction and guidance, need to better understand and control their processes. Real-time release testing (RTRT) and Quality by Design (QbD) are promoted by regulators as their vision of where quality must go; pharmacopeia guidance supports that vision. Cobalt has developed a successful, patented, high speed quantitative analysis technology called transmission Raman spectroscopy (TRS), which measures drug potency of intact tablets and capsules. When used during production (“on-line”) in combination with an automated physical tablet testing system, TRS will enable immediate release of drug product without “off-line” analysis in a quality control (QC) laboratory.

Keywords: pharmaceutical manufacture,raman,spectroscopy,testing,quality control
Actions for Excellence in Smart Cyber-Physical Systems applications through exploitation of Big Data in the context of Production Control and Logistics (EXCELL)

Framework: Horizon 2020 — Spreading excellence and widening participation
Programme: Widening participation and spreading excellence
Theme: Improved access to Excellence
Action type: Coordination and support actions
Countries involved: Germany,Belgium,Hungary,United Kingdom
Call: Twinning (H2020-TWINN-2015, 2015)
Start date: 2016-01-01
End date: 2018-12-31
Duration (months): 36.0
Total project cost (EUR): 996775.0
EU funding (EUR): 996775.0
Participants: 4
Project status: CLOSED

EXCELL foresees the collaboration of academics from 4 EU countries (HU, DE, UK, BE) in the multidisciplinary topic of Big Data Applications for Cyber-Physical Systems in Production and Logistics Networks. The main scientific and innovation focus of EXCELL was devised both from world-wide tendencies and local requirements (expressed by the regional S3), departing from the present competences of the cooperating partners (SZTAKI, Fraunhofer-FIT, Aston, and KU Leuven). Main project actions focus on: • Knowledge acceleration through transnational secondments and training sessions in 8 selected Priority Research Fields (PRFs) and 6 Complementary Skills, • Supporting exploitation of research results and user-driven innovation, • Augmenting scientific impact actions through key publications and active participation in the scientific discourse, • Dissemination and sustainable innovation. The 8 PRFs are: 1.Cyber-Physical Systems and Human System Interaction (responsible Fraunhofer), 2.Business-based Internet of Things and Services (resp. Fraunhofer), 3.Next-generation Authentication and Authorization Solutions (resp. KU Leuven), 4.Enhanced Context-aware Services (resp. KU Leuven), 5.Cognitive modelling and social networking approaches (resp. ASTON), 6.Data mining (resp. ASTON), 7.Data interoperability (resp. SZTAKI), 8.Tracking and tracing (resp. SZTAKI). The Complementary Skills include: Technology transfer and results deployment to industry, Emotional intelligence, Motivating others, Personal impact, Stress management for managers, and Hands-on experience by using and contributing to software tools. EXCELL activities are aligned towards 4 major types of impact: 1. Scientific impact, 2. Industry-driven innovation and technology transfer, 3. Sustainability and exploitation, 4. General and societal engagement, enabling strategic growth in both cross-sector and cross-regional cooperation, and sustainable scientific capabilities of all staff/institutions involved.

Keywords: scientific training,transversal skills training,transnational secondments,technology transfer academia industry,cross regional innovation
EXPLORING THE NEUROLOGICAL EXPOSOME (NEUROSOME)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Innovative Training Networks (ITN)-European Training Networks
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Spain,Italy,Italy,Spain,Italy,Slovenia,Belgium,Greece,Croatia,Greece,France,United States
Call: Innovative Training Networks (H2020-MSCA-ITN-2017, 2017)
Start date: 2017-10-01
End date: 2022-03-31
Duration (months): 54.0
Total project cost (EUR): 3427305.06
EU funding (EUR): 3427305.06
Participants: 16
Project status: CLOSED

The main objective of NEUROSOME is to develop an integrative biology-based framework starting from human biomonitoring data to unravel causal associations among the genetic predisposition, cumulative exposure to multiple environmental chemicals and neurological disorders. The project brings together beyond- the-state-of-the-art advances in human biomonitoring and systems biology, exposure monitoring and toxicological testing technologies and advanced tools for computational analyses of the exposure-to-health effect continuum following an exposome paradigm. The NEUROSOME methodology will be applied in population studies across different exposure settings to neurotoxicants (metals and persistent organics) in Europe. This will improve scientific knowledge on cause and-effect relations between environmental stressors and neurodevelopmental disorders taking into account exposure and health effect modification due to intrinsic (e.g. genetic susceptibility) and extrinsic (e.g. diet and socioeconomic status) factors. New standards for human biomonitoring data interpretation in conjunction with environmental and exposure information will be developed for ready use in chemical mixture risk assessment. The training goal is to produce a new generation of exposome researchers, trained in academia, applied research and industry, with transdisciplinary skills (environmental end exposure modelling, human biomonitoring, -omics technologies, high dimensional bioinformatics and environmental epidemiology,) and understanding of fundamental science and its direct application to environmental health challenges. To this aim NEUROSOME will focus on the provision of trans-disciplinary research training to young researchers through a combination of network-wide training programs and individual personalised training-through-research projects to deliver to the EU and the world a new cohort of researchers trained in cutting edge transdisciplinary environmental health sciences

Keywords: neurodevelopmental disorders,exposome,human biomonitoring,in vitro,in vivo testing,environmental exposure,gwas,ewas,personal sensors
The Mobi Charger, a novel mobile Electric Vehicle charging station that requires no installation costs, offers easy scalability and utility bill savings for users. (Mobi)

Framework: Horizon 2020 — Societal Challenges
Programme: Smart, green and integrated transport
Action type: SME instrument
Countries involved: Latvia,United Kingdom
Call: Small business innovation research for Transport and Smart Cities Mobility (H2020-SMEINST-1-2016-2017, 2016)
Start date: 2016-09-01
End date: 2016-12-31
Duration (months): 4.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 2
Project status: CLOSED

FreeWire’s Mobi is a novel, mobile charging station that brings the charge to the vehicle. Mobi’s charging infrastructure is easily scalable and uses onboard second-life EV batteries to create networks of grid-smart EV chargers. Mobi is capable of dual Level 2 and Level 3 Fast Charging, as is linked to a full-featured software platform. Each can add 60 km of range in half an hour. The mobility allows customers to avoid high infrastructure costs and underutilisation that plague traditional fixed charging stations, while also delivering a cost-effective solution to quickly scale up capacity. Deployments can be rolled out in days and EV drivers no longer have to waste time looking for an available charging station.

Keywords: mobile ev charger,greenhouse emissions,fossil fuels,electric vehicles,off peak,second life lithium ionbatteries,fast charging
Next Generation Smart Active Inceptors System development for Tilt Rotor application (SAIS)

Framework: Horizon 2020 — Societal Challenges
Programme: Smart, green and integrated transport
Theme: Public-private partnerships
Destination: Clean Sky 2
Action type: Innovation actions
Partnership: CS2 (Art-187)
Countries involved: Italy,Italy,Italy
Call: Smart Active Inceptors System development for Tilt Rotor application (H2020-CS2-CFP10-2019-01, 2019)
Start date: 2020-06-01
End date: 2023-11-30
Duration (months): 42.0
Total project cost (EUR): 4894464.38
EU funding (EUR): 3500000.07
Participants: 5
Project status: SIGNED

The SAIS project is aimed at designing, developing, manufacturing and qualifying a smart active inceptors system for the cockpit of the next generation civil tiltrotor. The design will focus on inceptors’ mechanical interfaces and at the same time studies on ergonomics, electromechanical senso-actuators, haptic capabilities, command logic including diagnostic capabilities will be part of SAIS commitment. The project will culminate with the achievement of SOF (Safety of Flight) qualification of the system in order to permit flight trials activities, and with the delivery of one EFA shipset to be installed on NGCTR-TD aircraft. Support to WAL for integration into Flight Control System (FCS) rig and into NGCTR-TD cockpit, at WAL’s facility, is part of the final goal. Starting from a preliminary system specification provided by WAL at the project start, the SAIS consortium will compile the compliance matrix to be issued at SRR, then the consortium will proceed with the system design, in order to achieve the best inceptor configuration, by considering weight, volumes, power consumption, complexity, integration, availability, reliability and ergonomics as KPIs. Trade-off activities and a technological innovation assessment with the final aim to identify the possible ergonomic architectures that match the WAL requirements and the tilt rotor specific application will be performed. The system will be integrated into FCS rig and into Tilt-Rotor cockpit at WAL premises’. A modeling and simulation tool of the flight control inceptors will be also developed and shared with WAL in order to support NextGen CTR FCS. During the development, special care will be dedicated at exploring and assessing mechanical designs and solutions, which enhance piloting effectiveness for tiltrotor application, at improving functionalities by capitalizing on active features by introducing world-class innovations for such a kind of equipment.
Computational biomechanics and bioengineering 3D printing to develop a personalized regenerative biological ventricular assist device to provide lasting functional support to damaged hearts (BRAV3)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Treating and managing disease
Action type: Research and Innovation actions
Countries involved: Germany,Spain,Spain,Spain,Ireland,Italy,Spain,Spain,Belgium,Netherlands,Netherlands,Netherlands,Portugal
Call: Regenerative medicine: from new insights to new applications (H2020-SC1-2019-Single-Stage-RTD, 2019)
Start date: 2020-01-01
End date: 2024-12-31
Duration (months): 60.0
Total project cost (EUR): 8000000.0
EU funding (EUR): 8000000.0
Participants: 17
Project status: SIGNED

Ischemic heart disease is the main cause of death in the EU, straining patients and economies. Regenerative Medicine has failed at delivering a definitive solution, and even the breakthrough of cell reprogramming, biomaterials or 3D printing, have not been able to find a curative solution. Generating a muscle with efficient pumping requires a careful recapitulation of the myocardial architecture. BRAV∃ is born with the ambition of shaping this quantum leap in the field. The overall concept is to provide a lasting functional support to injured hearts through the fabrication of regenerative personalized advanced tissue engineering-based biological ventricular assist devices (BioVADs). To do so, we will apply multimodal deep cardiac phenotyping, coupled to advanced Computational Modelling and biomechanical analysis in a large animal model of disease, to create a personalised 3D printable design. We will for the first time create a fibre-reinforced human heart-sized cardiac tissue able to recapitulate the low Young´s Modulus of the myocardium while withstanding pressures generated during the cardiac circle. Using the latest human induced pluripotent stem cell (hiPSC) technology and industrial-scale growth and differentiation, we will cellularize this novel human heart-sized constructs, creating a highly efficiently aligned cardiac tissue (including vasculature). BioVADs will be matured in in-Consortium built electromechanical stimulation bioreactors before transplantation in a porcine model of disease. We anticipate our BioVADs will constitute a one-shot regenerative treatment of IHD, decreasing the burden on healthcare providers and improving the quality of life of patients. Crucially, we will for the first time generate a wealth of information on heart development at a human scale. Delivering this novel application whilst developing the technological environment (bioreactor, chamber, pacemaker) will boost the capacity of the EU to grow economically and lead the field.

Keywords: cardiac disease,computational modelling,cardiac imaging,hipsc,cardiac tissue engineering,3d printing,biomaterials,industrial scale cell productionandmaturation,biomechanics,human organogenesis